A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment

Vox Sanguinis

Volumn 109, Issue 4, 2015, Pages 343-352

  Knutson, F ^a   Osselaer, J ^b   Pierelli, L ^c   Lozano, M ^d   Cid, J ^d   Tardivel, R ^e   Garraud, O ^e   Hervig, T ^f   Domanovic, D ^g   Cukjati, M ^g   Gudmundson, S ^h   Hjalmarsdottir, I B ^h   Castrillo, A ⁱ   Gonzalez, R ⁱ   Brihante, D ^j   Santos, M ^j   Schlenke, P ^k   Elliott, A ^l   Lin, J S ^l   Tappe, D ^l   Stassinopoulos, A ^l   Green, Jennifer M ^l   Corash, L ^l   more..

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d HOSPITAL CLÍNIC   (Spain)

^e ETABLISSEMENT FRANÇAIS DU SANG   (France)

^f UNIVERSITY OF BERGEN   (Norway)

^g BLOOD TRANSFUSION CENTRE OF SLOVENIA   (Slovenia)

^h LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

ⁱ Galicia Blood Transfusion Center   (Spain)

^j INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^k MEDICAL UNIVERSITY OF GRAZ   (Austria)

^l CERUS CORPORATION   (United States)

more..

Author keywords

Amotosalen; Haemovigilance; INTERCEPT; Pathogen inactivation; Platelets; Safety

Indexed keywords

AMOTOSALEN; FUROCOUMARIN DERIVATIVE; PHOTOSENSITIZING AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAFETY; BLOOD TRANSFUSION REACTION; CHILD; CHILL; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HEMATOLOGY EQUIPMENT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; ULTRAVIOLET A RADIATION; URTICARIA; ADVERSE EFFECTS; DRUG EFFECTS; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; PROSPECTIVE STUDY; RADIATION RESPONSE; STATISTICS AND NUMERICAL DATA; THROMBOCYTE; ULTRAVIOLET RADIATION; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; BLOOD SAFETY; CHILD; CHILD, PRESCHOOL; FEMALE; FUROCOUMARINS; HUMANS; INFANT; MALE; MIDDLE AGED; PHOTOSENSITIZING AGENTS; PLATELET TRANSFUSION; PROSPECTIVE STUDIES; ULTRAVIOLET RAYS;

EID: 84944271950     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12287     Document Type: Article

References (27)

1. van Rhenen D, Gulliksson H, Cazenave JP, et al.: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101:2426-2433
2. McCullough J, Vesole DH, Benjamin RJ, et al.: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 10:1534-1541
3. Janetzko K, Cazenave JP, Kluter H, et al.: Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45:1443-1452
4. http://www.who.int/bloodsafety/haemovigilance/en/ Accession date 10 April 2015.
5. de Vries RR, Faber JC, Strengers PF: Haemovigilance: an effective tool for improving transfusion practice. Vox Sang 2011; 100:60-67
6. Faber JC: Work of the European Haemovigilance Network (EHN). Transfus Clin Biol 2004; 11:2-10
7. Faber JC: Haemovigilance in Europe: the European Haemovigilance Network. Transfus Clin Biol 2001; 8:285-290
8. Andreu G, Morel P, Forestier F, et al.: Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994-1998. Transfusion 2002; 42:1356-1364
9. Osselaer JC, Cazenave JP, Lambermont M, et al.: An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94:315-323
10. Osselaer JC, Messe N, Hervig T, et al.: A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48:1061-1071
11. Willaert B, Vo Mai MP, Caldani C. French haemovigilance data on platelet transfusion. Transfus Med Hemother 2008; 35:118-121
12. Corash L, Lin JS, Sherman CD, et al.: Determination of acute lung injury after repeated platelet transfusions. Blood 2011; 117:1014-1020
13. Agence Francaise de Securite Sanitaire des Produits de Sante. Rapport Annuel hemovigilance 2001. Paris, Agence Francaise de Securite Sanitaire des Produits de Sante, 2001
14. Grass JA, Wafa T, Reames A, et al.: Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93:3140-3147
15. Domen RE, Hoeltge GA: Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 2003; 127:316-320
16. Enright H, Davis K, Gernsheimer T, et al.: Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 2003; 43:1545-1552
17. Agence Francaise de Securite Sanitaire des Produits de Sante. Rapport Annuel Hemovigilance 2009. Paris, Agence Francaise de Securite Sanitaire des Produits de Sante, 2009
18. Agence Francaise de Securite Sanitaire des Produits de Sante. Rapport Annuel Hemovigilance 2010. Paris, Agence Francaise de Securite Sanitaire des Produits de Sante, 2010
19. Agence Nationale de Securite du Medicament et des Produits de Sante (2011). Rapport Annuel Hemovigilance 2011. Paris, Agence Nationale de Securite du Medicament et des Produits de Sante, 2011
20. Agence Nationale de Securite du Medicament et des Produits de Sante. Rapport Annuel Hemovigilance 2012. Paris, Agence Nationale de Securite du Medicament et des Produits de Sante, 2012
21. Swissmedic Haemovigilance Annual Report 2010, 2010
22. Swissmedic Haemovigilance Annual Report 2012, 2012
23. Swissmedic Haemovigilance Annual Report 2013, 2013
24. Cazenave JP, Waller C, Kientz D, et al.: An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010; 50:1210-1219
25. Swissmedic Haemovigilance Annual Report 2008, 2008
26. Cazenave JP, Isola H, Waller C, et al.: Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51:622-629
27. Tobian AA, Fuller AK, Uglik K, et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion 2014; 54:1523-1529; quiz 1522